Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Google 2009 PageRank: #2 Among Top Health News and Media Publications
Google 2009 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2009 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2009 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
2009 OCT 19 ... including Hepatitis C and other viral infections, obesity, chronic alcohol abuse or autoimmune diseases. Conatus was founded by the executive management team of Idun Pharmaceuticals ...
2009 SEP 28 ... ligand for a subset of CD1d-restricted NKT cells, which could regulate experimental autoimmune encephalomyelitis, a murine model for multiple sclerosis, as well as tumor immunity and ... a murine model for multiple sclerosis, as well as tumor immunity and experimental hepatitis. Native sulfatide is a mixture of sulfatide isoforms, i.e. sulfatide molecules with ...
2009 OCT 19 ... minocycline is unique in causing a significant incidence of a lupus-like syndrome and autoimmune hepatitis. It is also unique among the tetracyclines in having a para-N, N-dimethylaminophenol ...
2009 NOV 16 ... receptors for potential applications in chronic hepatitis C virus infection and autoimmune diseases, and to support our partnered programs in oncology, respiratory disease, and ...
2009 NOV 23 ... biotechnology company focused on the development of new types of antiviral and autoimmune drugs. The Kineta team has a track record of developing novel drug classes to treat a ... to develop novel adjuvants to support the development of an effective vaccine against hepatitis C virus." Dr. Gale's laboratory has been instrumental in defining the ...
2009 NOV 16 ... Vertex's product pipeline is focused on viral diseases, cystic fibrosis, inflammation, autoimmune diseases, cancer, and pain. Vertex co-discovered the HIV protease inhibitor, Lexiva, ... More than 80 percent of hepatitis C patients in each arm of the Phase 2 Study C208 achieved a sustained viral response ...
2009 OCT 12 ... the detailed clinical and pathologic features of 3 patients who presented with chronic/autoimmune hepatitis alone while oil minocycline ill our hospital over a 2-year period," scientists in the ...
2009 OCT 5 ... A (Con A)-induced hepatitis is a T-cell-mediated murine experimental model of autoimmune hepatitis. Mice lacking Valpha14 NKT cells were found to be less sensitive to this hepatitis and ...
2009 NOV 2 ... vs 1.7 percent) were similar in the double-blind and open-label periods, respectively. Autoimmune events occurred at a similar rate in the double-blind and open-label periods (2.5 vs 1.3 ... develops a serious infection. Patients should be screened for tuberculosis, and viral hepatitis in accordance with published guidelines, and if positive, treated according to standard ...
2009 NOV 9 ... of IgM antibodies against hepatitis A virus (HAV), HAV infections can be regarded as autoimmune hepatitis when they show positive auto-antibodies by indirect immunofluorescence and lack other ...
2009 NOV 23 ... 4RN, Oxon, England. Keywords: City:Irvine, State:CA, Country:United States, Autoimmune Disease, Autoimmune Disorder, Central Nervous System, Central Nervous System Disease, ... nervous system (CNS) following infection with the neurotropic JHM strain of mouse hepatitis virus (JHMV) is associated with an immune-mediated demyelinating disease. Treatment of ...
2009 NOV 23 ... NASH. All were negative for other liver diseases such as hepatitis C, hepatitis B, autoimmune hepatitis, Wilson disease, and hemochromatosis. The patients (4 males and 3 females, age 63 +/- 13 ...
2009 SEP 28 ... 'The role of Ifng in alterations in liver gene expression in a mouse model of fulminant autoimmune hepatitis,' is newly published data in Liver International. "BALB/c mice with a homozygous ...
2009 SEP 21 ... association of K19 with human disease and no known association of K8/K18/K19 with human autoimmune liver disease. We tested the hypothesis that K8/K18/K19 variants associate with primary ... carriers to the development of end-stage liver disease and patients with chronic hepatitis C to disease progression. Hepatocytes express K8/K18, whereas biliary epithelia express ...
2009 NOV 23 ... 33 per cent (n = 20,305) of OLTs were secondary to hepatitis C virus, 21 per cent autoimmune disease, 17 per cent alcohol-induced injury, 11 per cent cryptogenic cirrhosis, 8 per ...
2009 NOV 16 ... including PEGINTRON, may cause or aggravate fatal or life-threatening neuropsychiatric, autoimmune, ischemic, and infectious disorders. Patients should be monitored closely with periodic ... the U.S. for use in combination with REBETOL=AE (ribavirin) for the treatment of chronic hepatitis C in patients 3 years of age and older with compensated liver disease. The ...
2009 OCT 12 ... Vertex's product pipeline is focused on viral diseases, cystic fibrosis, inflammation, autoimmune diseases, cancer, and pain. Vertex co-discovered the HIV protease inhibitor, Lexiva, ... data from Study C208, which evaluated twice-daily dosing of Vertex's investigational hepatitis C virus (HCV) protease inhibitor telaprevir, will be presented in an oral presidential ...
2009 OCT 12 ... Vertex's product pipeline is focused on viral diseases, cystic fibrosis, inflammation, autoimmune diseases, cancer, and pain. Vertex co-discovered the HIV protease ... and is leading the development of late-stage drug candidates aimed at the treatment of hepatitis C virus infection and cystic fibrosis," said Matthew Emmens, chairman, president and ...
2009 OCT 12 ... Vertex's product pipeline is focused on viral diseases, cystic fibrosis, inflammation, autoimmune diseases, cancer, and pain. Vertex co-discovered the HIV protease ... Vertex is eligible to receive from Janssen Pharmaceutica for the launch of Vertex's hepatitis C virus (HCV) protease inhibitor telaprevir in Europe. Vertex's collaboration with ...
